EPRX Stock Overview
A clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Eupraxia Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$3.09 |
| 52 Week High | CA$5.58 |
| 52 Week Low | CA$2.20 |
| Beta | 1.56 |
| 1 Month Change | -7.91% |
| 3 Month Change | 16.86% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 10.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| EPRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.2% | -1.7% | -1.1% |
| 1Y | n/a | -5.0% | 22.4% |
Return vs Industry: Insufficient data to determine how EPRX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how EPRX performed against the US Market.
Price Volatility
| EPRX volatility | |
|---|---|
| EPRX Average Weekly Movement | 12.3% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EPRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: EPRX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 29 | James Helliwell | www.eupraxiapharma.com |
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company’s lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology.
Eupraxia Pharmaceuticals Inc. Fundamentals Summary
| EPRX fundamental statistics | |
|---|---|
| Market cap | US$111.41m |
| Earnings (TTM) | -US$28.22m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.9x
P/E RatioIs EPRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EPRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$28.22m |
| Earnings | -US$28.22m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.79 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did EPRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 06:51 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Eupraxia Pharmaceuticals Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Gary Nachman | Raymond James & Associates |
| Rahul Sarugaser | Raymond James Ltd. |